

IN THE CLAIMS

Please amend the claims as follows:

Claims 1 (Currently Amended): A method for treating at least one inflammatory pathological skin condition in a subject in need thereof, comprising administering a composition comprising at least one soluble form of HLA-G and at least one pharmaceutically acceptable vehicle to the subject in an amount sufficient to treat the at least one inflammatory pathological skin condition, wherein the at least one soluble form of HLA-G is selected from the group consisting of the whole $\alpha 1$ extracellular domain of HLA-G, a whole soluble form of HLA-G1, a whole soluble form of HLA-G2, a whole soluble form of HLA-G3, a whole soluble form of HLA-G4, and a whole soluble form of HLA-G5.

Claim 2 (Cancelled).

Claim 3 (Previously Presented): The method of claim 1 wherein the composition comprises between 0.1 and 5 $\mu\text{g}/\text{m}$ of the at least one soluble form of HLA-G.

Claims 4-7 (Cancelled).

Claim 8 (Previously Presented): The method of claim 1, wherein the composition comprises between 0.5 and 2.5 $\mu\text{g}/\text{ml}$ of the at least one soluble form of HLA-G.

Claims 9-10 (Cancelled).

11. (New) The method of Claim 1, wherein the inflammatory skin condition is psoriasis.

12. (New) The method of Claim 1, wherein the at least one soluble form of HLA-G comprises a whole $\alpha 1$ extracellular domain of HLA-G.

13. (New) The method of Claim 1, wherein the at least one soluble form of HLA-G comprises a whole soluble form of HLA-G1.

14. (New) The method of Claim 1, wherein the at least one soluble form of HLA-G comprises a whole soluble form of HLA-G2.

15. (New) The method of Claim 1, wherein the at least one soluble form of HLA-G comprises a whole soluble form of HLA-G3

16. (New) The method of Claim 1, wherein the at least one soluble form of HLA-G comprises a whole soluble form of HLA-G4.

17. (New) The method of Claim 1, wherein the at least one soluble form of HLA-G comprises a whole soluble form of HLA-G5.